SU-DHL-2

SU-DHL-2 (Lymphoma CDX Model)

The SU-DHL-2 line was derived from a patient with diffuse large B-cell lymphoma (DLBCL). It represents aggressive B-cell malignancies. SU-DHL-2 has been extensively used in lymphoma drug discovery. Its consistent biology makes it a reliable translational research model.

Key Features:

• Derived from diffuse large B-cell lymphoma.
• Aggressive B-cell lymphoma phenotype.
• Suspension culture morphology.
• Tumorigenic in xenografts.

Applications:
SU-DHL-2 supports development of novel therapies for DLBCL. It is applied in biomarker validation and signaling pathway studies. Researchers employ it in drug resistance and therapeutic testing. Its reproducibility makes it valuable for translational hematology pipelines.